The US Food and Drug Administration has approved crinecerfont for treating congenital CAH in combination with glucocorticoids ...
The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback